Kyla Shea

Dr. Kyla Shea


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
KSKyla Shea
Kyla Shea
SKS.B. Kritchevsky
S.B. Kritchevsky
FHF.-C. Hsu
F.-C. Hsu
MNM. Nevitt
M. Nevitt
SBS.L. Booth
S.L. Booth
RLR.F. Loeser
R.F. Loeser

31 March 2016 in Current Nutrition Reports
Verified
Journal Article
Closed access
PDF file
SHStephanie G. Harshman
Stephanie G. Harshman
KSKyla Shea
Kyla Shea

1 May 2017 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
KSKyla Shea
Kyla Shea
SBSarah L Booth
Sarah L Booth
DWDaniel E Weiner
Daniel E Weiner
TBTina E Brinkley
Tina E Brinkley
AKAlka M Kanaya
Alka M Kanaya
SKStephen B Kritchevsky
Stephen B Kritchevsky
Background: A role for vitamin K in coronary artery calcification (CAC), a subclinical manifestation of cardiovascular disease (CVD), has been propos

1 January 2022 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
SBSarah L. Booth
Sarah L. Booth
KSKyla Shea
Kyla Shea
KBKathryn Barger
Kathryn Barger
SLSue E. Leurgans
Sue E. Leurgans
BJBryan D. James
Bryan D. James
JSJulie A. Schneider
Julie A. Schneider
Higher vitamin K intakes have been associated with better cognitive function, suggestive of a vitamin K mechanistic effect or simply reflective of a healthy diet. To test the hypothesis that brain vitamin K is linked to cognitive decline and dementia, vitamin K concentrations were measured in four brain regions, and their associations with cognitive and neuropathological outcomes were estimated in 325 decedents of the Rush Memory and Aging Project. Menaquinone‐4 (MK4) was the main vitamin K form in the brain regions evaluated. Higher brain MK4 concentrations were associated with a 17% to 20% lower odds of dementia or mild cognitive impairment (MCI) ( P ‐value < .014), with a 14% to 16% lower odds of Braak stage ≥IV ( P ‐value < 0.045), with lower Alzheimer's disease global pathology scores and fewer neuronal neurofibrillary tangles ( P ‐value < 0.012). These findings provide new and compelling evidence implicating vitamin K in neuropathology underlying cognitive decline and dementia.

3 March 2021 in Advances in Nutrition
Verified
Journal Article
Open access
PDF file
KSKyla Shea
Kyla Shea
KBKathleen L Berkner
Kathleen L Berkner
GFGuylaine Ferland
Guylaine Ferland
XFXueyan Fu
Xueyan Fu
RHRachel M Holden
Rachel M Holden
SBSarah L Booth
Sarah L Booth
A protective role for vitamin K in cardiovascular disease (CVD), a leading cause of morbidity and mortality, has been proposed because vitamin K–dependent proteins, such as matrix Gla (γ-carboxyglutamic acid) protein (MGP), are present in vascular tissue. MGP functions as a vascular calcification inhibitor—but only when it is carboxylated, which requires vitamin K. There is more than one naturally occurring form of vitamin K. Phylloquinone (vitamin K1) is found in plant-based foods, whereas menaquinones (vitamin K2) are a class of vitamin K compounds found in animal-based and fermented foods. Phylloquinone and menaquinones are capable of carboxylating MGP and other vitamin K–dependent proteins. In rodent models, high intakes of either phylloquinone or menaquinone reduced vascular calcification. Evidence of the relative importance of phylloquinone and menaquinone to CVD in humans is limited and controversial. In some observational studies, higher dietary menaquinone intake, but not phylloquinone intake, was associated with less coronary artery calcification (a subclinical manifestation of CVD) and a lower risk for clinical CVD events. These findings have led to claims that menaquinones have unique cardiovascular health benefits compared with phylloquinone. However, this claim is not supported by the results of the limited number of intervention trials conducted to date. The purpose of this review is to evaluate the strengths and limitations of the available evidence regarding the role of vitamin K in vascular calcification, CVD, and mortality.

1 January 2015 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
RHRachel M Holden
Rachel M Holden
SBSarah L Booth
Sarah L Booth
ADAndrew G Day
Andrew G Day
CCCatherine M Clase
Catherine M Clase
DZDeborah Zimmerman
Deborah Zimmerman
Daren HeylandDaren Heyland
Daren Heyland
Background: Cardiovascular disease, which is due in part to progressive vascular calcification, is the leading cause of death among patients with end stage kidney disease (ESKD) on dialysis. A role for vitamin K in the prevention of vascular calcification is plausible based on the presence of vitamin K dependent proteins in vascular tissue, including matrix gla protein (MGP). Evidence from animal models and observational studies support a role for vitamin K in the prevention of vascular calcification. A large-scale study is needed to investigate the effect of vitamin K supplementation on the progression of vascular calcification in patients with ESKD, a group at risk for sub-clinical vitamin K deficiency. Methods/Design: We plan a prospective, randomized, double-blind, multicenter controlled trial of incident ESKD patients on hemodialysis in centers within North America. Eligible subjects with a baseline coronary artery calcium score of greater than or equal to 30 Agatston Units, will be randomly assigned to either the treatment group (10 mg of phylloquinone three times per week) or to the control group (placebo administration three times per week). The primary endpoint is the progression of coronary artery calcification defined as a greater than 15% increase in CAC score over baseline after 12 months. Discussion: Vitamin K supplementation is a simple, safe and cost-effective nutritional strategy that can easily be integrated into patient care. If vitamin K reduces the progression of coronary artery calcification it may lead to decreased morbidity and mortality in men and women with ESKD. Trial registration: NCT 01528800.